TAK-438 - CAS# 881681-01-2 onic Acid (hydrate) and a reversal in osteoporotic

and a reversal in osteoporotic changes

[Epub ahead of print] PubMed PMID: 30126942

through Suppression of the HIF-1α/VEGF Signaling Pathway

2(6):407-12

InChi: InChI=1S/C17H24O10/c1-24-15(23)9-6-25-16(11-7(4-18)2-3-8(9)11)27-17-14(22)13(21)12(20)10(5-19)26-17/h2

TAK-438 - CAS# 881681-01-2 onic Acid (hydrate) and a reversal in osteoporoticTAK438, also known as Vonoprazan Fumarate, is a new medicine for treating acid related diseases with a novel mechanism of action called potassium competitive acid blockers (P CABs) which competitively inhibits the binding of potassium ions to H+, K+ ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. TAKECAB provides a strong and sustained acid secretion inhibitory effect. Product information